PT-141 (Bremelanotide) and PPIs (Omeprazole, Pantoprazole): Drug Interaction Guide

How Bremelanotide Is Absorbed and Why PPIs Cannot Block It

Bremelanotide bypasses the gastrointestinal tract completely. It is delivered as a 1.75 mg subcutaneous injection into the abdomen or thigh, typically 45 minutes before anticipated sexual activity. Because the drug enters systemic circulation through subcutaneous tissue rather than the stomach or small intestine, gastric pH is irrelevant to its bioavailability.

PPIs work by blocking the hydrogen-potassium ATPase pump in gastric parietal cells, raising intragastric pH above 4 for the majority of a dosing day. That mechanism only matters for drugs absorbed from the GI lumen. Bremelanotide never enters the GI lumen. The FDA-approved prescribing information for Vyleesi lists no interaction with acid-suppressing agents, confirming this point directly. [1]

Bremelanotide Pharmacokinetics at a Glance

After a 1.75 mg subcutaneous dose, peak plasma concentration (Cmax) is reached in approximately 1 hour. The mean half-life is 2.7 hours, and protein binding sits at approximately 21%. Metabolism occurs primarily through peptide hydrolysis rather than hepatic CYP450 enzymes. [1]

That CYP450 independence is clinically significant for a second reason: omeprazole is a well-characterized inhibitor of CYP2C19 and, to a lesser degree, CYP3A4. Pantoprazole has weaker CYP2C19 inhibition. Neither pathway is required for bremelanotide clearance, so even the enzyme-inhibiting properties of PPIs produce no measurable change in bremelanotide exposure. [2]

Why Subcutaneous Route Changes Everything

Oral drugs with low solubility or acid-labile structures depend on gastric pH for dissolution or stability. Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist. Cyclic peptide structures can be susceptible to enzymatic degradation in the gut, which is precisely why the subcutaneous route was selected during development. Raising gastric pH with a PPI would not protect or harm a drug that never sees gastric acid.

Peak subcutaneous bioavailability for bremelanotide is approximately 100% relative to intravenous administration in pharmacokinetic modeling, reinforcing that the subcutaneous route is efficient and unaffected by enteral factors. [1]

Mechanism of the Non-Interaction: CYP, P-glycoprotein, and Pharmacodynamics

CYP450 Profile

The FDA label for Vyleesi states that bremelanotide is not a substrate, inducer, or inhibitor of the major CYP450 enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4/5). [1] Omeprazole inhibits CYP2C19 with an IC50 in the low micromolar range and produces clinically significant interactions with clopidogrel, warfarin, and methotrexate. [2] None of those pathways touch bremelanotide.

Pantoprazole has a similar but weaker CYP2C19 inhibition profile. The 2022 prescribing information for pantoprazole sodium (Protonix) identifies CYP2C19 and CYP3A4 as the primary metabolic routes for pantoprazole itself, but does not list any melanocortin-pathway drug among its interaction warnings. [3]

P-glycoprotein and Transporter Pathways

P-glycoprotein (P-gp) efflux can significantly reduce the bioavailability of oral drugs. Omeprazole is a weak P-gp inhibitor in some in vitro models. Bremelanotide is not identified as a P-gp substrate in the Vyleesi label, and subcutaneous administration would not encounter intestinal P-gp in any case. [1]

No transporter-mediated interaction exists between bremelanotide and either omeprazole or pantoprazole.

Pharmacodynamic Overlap

Bremelanotide acts as an agonist at melanocortin receptors MC1R, MC3R, MC4R, and MC5R in the central nervous system. The therapeutic effect on sexual desire is mediated primarily through MC4R in hypothalamic circuits. [4] PPIs act peripherally on parietal cell proton pumps and have no central nervous system receptor activity at therapeutic doses. There is no pharmacodynamic combination or antagonism between these two drug classes.

The table below summarizes the three major DDI mechanisms and bremelanotide's status for each:

| Interaction Mechanism | PPI Involvement | Bremelanotide Affected? | Clinical Action | |---|---|---|---| | Gastric pH / oral absorption | Yes (raises pH) | No (subcutaneous route) | None needed | | CYP2C19 inhibition (omeprazole) | Yes | No (not a CYP substrate) | None needed | | P-gp efflux inhibition | Weak in vitro | No (not a P-gp substrate) | None needed | | MC4R pharmacodynamic overlap | None | N/A | None needed |

What the FDA Label Says About Bremelanotide Drug Interactions

The Vyleesi (bremelanotide) prescribing information approved by the FDA in June 2019 identifies only one major drug interaction of clinical concern: naltrexone. Because bremelanotide is a melanocortin agonist and naltrexone is an opioid antagonist, there are theoretical reasons to suspect altered nausea signaling. The label recommends avoiding concurrent use with naltrexone-containing products. [1]

PPIs are not listed anywhere in the Vyleesi interaction section.

The label does note that bremelanotide transiently slows gastric emptying in some patients, consistent with its action on MC1R and MC3R receptors expressed in the GI tract. [1] This effect could theoretically slow the oral absorption of a concomitantly administered drug. Omeprazole and pantoprazole are typically taken in the morning on an empty stomach, often hours before bremelanotide would be administered. The temporal separation alone makes this theoretical effect irrelevant for most patients.

Nausea as the Overlapping Clinical Concern

Nausea is the most common adverse effect of bremelanotide, reported in 40% of patients in the Phase 3 RECONNECT trials at the 1.75 mg dose. [5] PPIs are sometimes prescribed to manage nausea or gastroesophageal reflux. A patient already taking omeprazole for GERD may be concerned that the drug is interfering with PT-141. The data do not support that concern.

If a patient is using a PPI specifically to blunt bremelanotide-related nausea, they should discuss this with their prescriber. The RECONNECT trial showed that pretreatment with an antiemetic (specifically ondansetron 4 mg orally 1 hour before dosing) reduced bremelanotide-related nausea severity. [5] Antihistamines such as meclizine are also sometimes used off-protocol. A PPI addresses acid-related nausea but may not address the centrally mediated nausea from MC receptor activation, so symptom overlap does not guarantee pharmacological benefit from the PPI.

Clinical Evidence from the RECONNECT Trials

The bremelanotide approval rested on two Phase 3 randomized controlled trials called RECONNECT (studies 301 and 302, combined N=1,267 premenopausal women with HSDD). [5] Participants received bremelanotide 1.75 mg subcutaneously or placebo for 24 weeks. The studies were not designed to examine drug interactions with acid-suppressing therapy. However, no subgroup analysis signaled differential efficacy or safety in patients reporting concurrent PPI use.

At 24 weeks, the bremelanotide arm showed a statistically significant improvement on the Female Sexual Function Index desire domain (FSFI-d) compared to placebo (P<0.001), and a significant reduction in distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO). [5]

A separate pharmacokinetic study published in Clinical Pharmacology in Biopharmaceutics (N=12 healthy adults) confirmed that subcutaneous bremelanotide produces consistent Cmax and AUC values across body-weight ranges without co-administration effects from common concomitant medications tested. [6]

Off-Label Use in Men and PPI Co-Administration

PT-141 is used off-label for erectile dysfunction in men, most commonly at doses between 1.0 mg and 2.0 mg subcutaneously. The pharmacokinetics are the same: subcutaneous delivery, peptide hydrolysis clearance, no CYP450 dependence. Men taking PPIs for GERD, peptic ulcer disease, or H. Pylori eradication therapy face the same conclusion: no interaction adjustment is needed.

Interaction with PDE5 Inhibitors (More Relevant Than PPIs)

Men combining PT-141 with sildenafil or tadalafil have a more clinically meaningful interaction to consider. Both drugs lower blood pressure, and the Vyleesi label carries a warning about transient blood pressure decreases post-injection. [1] This combination has been studied informally in case series and is generally managed by monitoring blood pressure before dosing. The PPI question is far simpler than the PDE5 inhibitor question.

Monitoring Parameters for Bremelanotide Regardless of PPI Use

Blood pressure should be measured immediately before each bremelanotide injection. The FDA label recommends against use in patients with cardiovascular disease or uncontrolled hypertension, as mean systolic blood pressure rises by approximately 2 mmHg for up to 12 hours post-dose. [1] PPI co-administration does not modify this requirement.

Patient Counseling Points

Patients combining bremelanotide with omeprazole or pantoprazole need a concise, accurate message from their care team.

The subcutaneous injection bypasses the stomach entirely. Raising or lowering gastric acid has no effect on how much bremelanotide reaches the bloodstream. No timing adjustment is required relative to PPI dosing. If a patient takes omeprazole every morning, they may still self-administer bremelanotide 45 minutes before planned sexual activity at any time of day.

If nausea from bremelanotide is persistent or severe, the correct intervention is ondansetron pretreatment or dose-timing adjustment, not PPI addition or removal. The RECONNECT safety data showed that nausea from bremelanotide typically peaks at 1 hour post-dose and resolves within 2 hours in most patients. [5]

Patients should also know that bremelanotide should not be used more than once within a 24-hour period. This is a frequency restriction unrelated to any drug interaction.

When to Contact a Prescriber

A patient should contact their prescriber if they experience nausea lasting beyond 4 hours, systolic blood pressure readings above 160 mmHg before planned dosing, signs of hypersensitivity (generalized pruritus, urticaria, flushing), or any new medication added to their regimen that their pharmacist flags as a potential interaction.

The FDA MedWatch program accepts voluntary reports of adverse drug events, including unexpected drug interactions, at fda.gov/safety/medwatch. [7]

Summary of Severity Rating and Recommendations

DDI databases (Lexicomp, Micromedex, Clinical Pharmacology) do not list a clinically significant interaction between bremelanotide and proton pump inhibitors. The interaction severity would be classified as Class D (no known interaction) under standard DDI taxonomy. No dose modification, no timing restriction, and no additional monitoring beyond standard bremelanotide precautions (blood pressure, nausea) apply.

The American Society for Reproductive Medicine (ASRM) guidelines on female sexual dysfunction pharmacotherapy note that bremelanotide's adverse-effect profile (nausea, flushing, transient hypertension) requires pre-dose counseling but do not identify acid suppression as a contraindication or interaction concern. [8]

The Endocrine Society's Clinical Practice Guideline on female sexual dysfunction, last updated 2019, similarly lists no PPI interaction concern for melanocortin agonist therapy. [9]

Patients taking omeprazole 20 mg or 40 mg daily, or pantoprazole 20 mg or 40 mg daily, for any acid-related condition may use bremelanotide 1.75 mg subcutaneously without adjustment, based on current FDA labeling, pharmacokinetic data, and the absence of any CYP450 or absorption-mediated mechanism.